Zobrazeno 1 - 10
of 150
pro vyhledávání: '"M Sue, O'Dorisio"'
Autor:
Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Casey Pulliam, Keegan A. Christensen, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
Thioredoxin Reductase (TrxR) functions to recycle thioredoxin (Trx) during hydroperoxide metabolism mediated by peroxiredoxins and is currently being targeted using the FDA-approved anti-rheumatic drug, auranofin (AF), to selectively sensitize cancer
Externí odkaz:
https://doaj.org/article/c5a3742216384e1498585e82c931ad1b
Autor:
Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Bryan G. Allen, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath
Publikováno v:
bioRxiv
Thioredoxin Reductase (TrxR) is a key enzyme in reactive oxygen species (ROS) detoxification and in redox regulation. Because cancer cells produce increased steady-state levels of ROS (i.e., superoxide and hydrogen peroxide), TrxR is viable target in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db2b29a43eee17c37e62aa5bb71f97e
https://doi.org/10.1101/2023.05.07.539772
https://doi.org/10.1101/2023.05.07.539772
Autor:
Abhishek Jha, Kristine de Luna, Charlene Ann Balili, Corina Millo, Cecilia Angela Paraiso, Alexander Ling, Melissa K. Gonzales, Bruna Viana, Rami Alrezk, Karen T. Adams, Isabel Tena, Alice Chen, Jiri Neuzil, Margarita Raygada, Electron Kebebew, David Taieb, M. Sue O'Dorisio, Thomas O'Dorisio, Ali Cahid Civelek, Constantine A. Stratakis, Leilani Mercado-Asis, Karel Pacak
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Pheochromocytoma and paraganglioma (PHEO/PGL) are rare neuroendocrine tumors which may cause potentially life-threatening complications, with about a third of cases found to harbor specific gene mutations. Thus, early diagnosis, treatment
Externí odkaz:
https://doaj.org/article/3cb9302e5ead419f910f1ecd3cb52a7d
Autor:
David L. Bushnell, M. Sue O'Dorisio, K D Zamba, Thomas M. O'Dorisio, Janet H Pollard, Mark T. Madsen, Yusuf Menda
Publikováno v:
Cancer Biother Radiopharm
Background: Histone deacetylase (HDAC) inhibitors have been shown in preclinical studies to upregulate norepinephrine transporters in neuroblastoma and pheochromocytoma, and somatostatin receptors in pulmonary carcinoid, small cell lung cancer, and p
Autor:
Melissa A. Fath, Dijie Liu, Claudia Robles-Planells, Jordan T. Ewald, Keegan A. Christensen, Spenser S. Johnson, Stephen A. Graves, Douglas R. Spitz, Yusuf Menda, M. Sue O’Dorisio
Publikováno v:
Cancer Research. 83:5034-5034
Introduction/Background: Atypical lung carcinoids and lung neuroendocrine carcinomas (NECs) are currently incurable. Most of these cancers express the C-X-C chemokine receptor 4 (CXCR4), making CXCR4 an attractive target for cancer diagnosis and trea
Autor:
Stephen A. Graves, Yusuf Menda, David L. Bushnell, Thomas M. O'Dorisio, Kellie L. Bodeker, M. Sue O'Dorisio, Gideon K. D. Zamba, Mark T. Madsen
Publikováno v:
Journal of Nuclear Medicine. 62:1274-1277
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding 131I-metaiodobenzylguanid
Autor:
Deborah Theiler, Marco Cattaneo, Lawrence O. Dierickx, Peter Igaz, Simona Grozinsky-Glasberg, Claire Bournaud, Thomas O’Dorisio, M. Sue O’Dorisio, Damian Wild, Emanuel Christ, Guillaume P. Nicolas
Publikováno v:
Cancers, Vol 13, Iss 6290, p 6290 (2021)
Cancers
Cancers; Volume 13; Issue 24; Pages: 6290
Cancers
Cancers; Volume 13; Issue 24; Pages: 6290
Simple Summary We compared the safety and efficacy of targeted radionuclide therapy between elderly (79 years old and older) and disease-matched younger patients (between 60 and 70 years of age) with metastatic neuroendocrine tumour (NET). To our kno
Autor:
Catalina Abad, Bhavaani Jayaram, Laurine Becquet, Yuqi Wang, M. Sue O’Dorisio, James A. Waschek, Yossan-Var Tan
Publikováno v:
Journal of Neuroinflammation, Vol 14, Iss 1, Pp 1-1 (2017)
Externí odkaz:
https://doaj.org/article/74aabc677a7a4d60980f4a5c5a1aa19d
Autor:
Catherine G. Tran, Luis C. Borbon, Jacqueline L. Mudd, Ellen Abusada, Solmaz AghaAmiri, Sukhen C. Ghosh, Servando Hernandez Vargas, Guiying Li, Gabriella V. Beyer, Mary McDonough, Rachel Li, Carlos H.F. Chan, Susan A. Walsh, Thaddeus J. Wadas, Thomas O’Dorisio, M Sue O’Dorisio, Ramaswamy Govindan, Paul F. Cliften, Ali Azhdarinia, Andrew M. Bellizzi, Ryan C. Fields, James R. Howe, Po Hien Ear
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 1910
Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are rare cancers consisting of neuroendocrine carcinomas (NECs) and neuroendocrine tumors (NETs), which have been increasing in incidence in recent years. Few cell lines and pre-clinical mode
Autor:
David L, Bushnell, Kellie L, Bodeker, Thomas M, O'Dorisio, Mark T, Madsen, Yusuf, Menda, Stephen, Graves, Gideon K D, Zamba, M Sue, O'Dorisio
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62(9)
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding